This test (NAT) or nucleic acid amplification test (NAAT) is one of the advanced diagnostic tests that is gaining more and more strength over conventional culture methods, due to its high efficiency and precision. Furthermore, this test has potential application in various life-threatening diseases, such as cancer, infectious diseases, genetic and mitochondrial disorders, and also in the development of personalized and precision medicine. NAT is an efficient diagnostic method, which significantly reduces procedure time and reagent consumption. Furthermore, this test is increasingly being used to screen donated blood samples to reduce the risk of Transfusion-Transmitted Infections (TTIs), helping the growth of the nucleic acid testing market.

Nucleic Acid Testing Market – Driver

These tests are widely used for the detection and diagnosis of various infectious diseases. In addition, the increasing prevalence of infectious diseases and the management of epidemics of new diseases has led to a growing demand for advanced diagnostic tests, such as nucleic acid tests. For example, according to the World Health Organization (WHO), in 2015 there were around 32,000 estimated deaths from tuberculosis and around 3,23,000 new TB cases in the European region. In addition, according to the Centers for Disease Control and Prevention (CDC), there were about 5,251 deaths from influenza infection in the US in 2015. Infectious and parasitic diseases were reported in the US. The acid test Nuclear scanning (NAT) allows examination of various changes in gene sequence and copy number, and provides information about disease recurrence and the potential condition of the patient to respond to a particular treatment. Additionally, NAT can identify which patients have suffered from inherited mutations, which ultimately helps identify whether or not the patient is at increased risk of developing cancer. The increasing incidence of cancer in various geographic areas is a major factor driving the increasing adoption of nucleic acid testing. For example, according to Cancer Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012. In addition, India, China, and other countries in East and Central Asia accounted for almost half of all new cancer cases and deaths. of the world, in 2017. In addition, according to the same source, by 2025, there will be an estimated 19.3 million new cases of cancer and 11.4 million deaths from cancer, in less developed regions.

In addition, research funding from various government and private cancer treatment organizations and the increasing adoption of nucleic acid and molecular tests in cancer research programs to detect molecular genetic changes in unique sequences are expected to increase. or multiple DNA or mutations, help in the growth of the nucleic acid. acid testing market, in the near future. In 2016, the National Cancer Institute (NCI) invested $3.9 billion in cancer research activities, representing 70.8% of NCI’s overall budget for 2016. Among which, NCI invested about $ 533 million in research activities for the detection and diagnosis of cancer. Additionally, in 2016, NCI allocated 40.4% of its funding to Research Project Grants (RPGs). Additionally, in 2017, the NCI budget increased by $454 million (8.7%) over the previous year (2016) for research activities.

Customization Request @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1644

restricted market

The inability or difficulty of nucleic acid testing to obtain quantitative results from a large number of clinical samples, the difficulty of using the NAT test for susceptibility testing, and the increased cost of nucleic acid testing devices are expected to hinder the growth of the nucleic acid testing market. According to data published in the Asian Journal of Transfusion Science in February 2014, NAT is an advanced and highly sensitive technique; however, it is associated with high cost and requires dedicated infrastructure facilities, equipment, consumables, and technical expertise.

Market – Regional Analysis

Geographically, the global nucleic acid testing market is segmented into North America, Latin America, Europe, the Middle East, Asia Pacific, and Africa. North America occupies a dominant position in the nucleic acid testing market, followed by Europe. This is due to the increase in research and development studies conducted by various pharmaceutical and government organizations in the diagnosis of infectious diseases and cancer in North America. For example, in January 2018, the project led by the University of Glasgow received a grant of US$1.85 million, which is part of the Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid tests in remote locations to help enable rapid diagnosis and rapid treatment of infectious diseases. Furthermore, the high prevalence and awareness of cancer among people, in turn opting for early detection of cancer, is expected to help the growth of the nucleic acid testing market in this region. For example, according to American Cancer Society data results, North America had the highest incidence of childhood cancer compared to any other region in 2012. Additionally, North America accounted for 13.1% of the estimated total of cancer cases in 2012, worldwide. according to the same source.

Asia Pacific is expected to witness the fastest growth in the nucleic acid testing market during the forecast period. This is due to the growing demand for efficient and rapid diagnostic tests and the growing focus of major market players to expand their geographic reach in this region. For example, in March 2013, Qiagen NV launched its careHPV test in China. careHPV is a molecular diagnostic test designed to detect high-risk human papillomavirus (HPV) in low-resource settings, such as areas without electricity, water, or laboratories. Qiagen also gained approval from the China State Food and Drug Administration (SFDA) for careHPV in 2012.

Market – Competitive Analysis

Major market players in the nucleic acid testing market are Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, BioMérieux SA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Grifols , SA, Illumina, Inc., Novartis Ag, Qiagen NV, Quest Diagnostics Incorporated, Siemens Ag, and Tecan Group Ltd., among others. The players in the market are focusing on inorganic growth strategies, to improve their market share and remain competitive in the market. For example, in January 2017, Grifols, SA acquired the NAT (Nucleic Acid Testing) donor screening unit from Hologic, Inc. for $1.85 billion. The acquisition allowed Grifols to strengthen its position in transfusion medicine through NAT technology.

Market – Taxonomy

By product type

• Test equipment

  • Polymerase Chain Reaction (PCR)

  • Ligase chain reaction (LCR)

  • Transcription-mediated amplification (TMA)

  • Whole genome sequencing

• consumables

By indication

• infectious disease

• Cancer

• forensic evidence

• Personalized medicine

• others

By end user

• Hospitals and Clinics

• Pathology Laboratories

• Academic and research organization

By Geography:

• North America

• Latin America

• Europe

• Pacific Asia

• middle East

• Africa

About Coherent Market Insights:

Coherent Market Insights is a leading market research and consulting firm providing action-ready syndicated research reports, custom market analysis, advisory services and competitive analysis through various recommendations related to emerging market trends and technologies and absolute potential opportunities in dollars.

Contact Us:

mr shah

Consistent Market Outlook

1001 4th Avenue, #3200

Seattle, WA 98154

Phone: +1-206-701-6702

Email: [email protected]